PMID- 29892554
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2213-0489 (Print)
IS  - 2213-0489 (Electronic)
IS  - 2213-0489 (Linking)
VI  - 9
DP  - 2018
TI  - Incident adverse events following therapy for acute promyelocytic leukemia.
PG  - 79-83
LID - 10.1016/j.lrr.2018.05.001 [doi]
AB  - The use of all-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) 
      with or without cytotoxic chemotherapy is highly effective in acute promyelocytic 
      leukemia (APL) but incident chronic adverse events (AEs) after initiation of 
      therapy are not well understood. We retrospectively analyzed adult patients with 
      newly diagnosed APL from 2004 through 2014 to identify incident AEs following 
      treatment and contributing risk factors. Cardiac and neurologic AEs were more 
      common and characterized in detail. Cardiac AEs such as the development of 
      coronary artery disease (CAD), arrhythmias, and heart failure had a cumulative 
      incidence of 6.4% (CI95 1.8-11.1%), 2.9% (CI95 0.0-6.4%), 5.8% (CI95 1.2-10.3%) 
      at 4 years from diagnosis, respectively. In multivariate analyses of factors 
      influencing heart failure, the presence of clinical or radiographic CAD (HR 4.25; 
      P = 0.011) or troponin elevation prior to completion of therapy (HR 8.86; 
      P = 0.0018) were associated with increased heart failure incidence, but not 
      anthracycline use or dose. Neurological AEs were common following therapy; at 4 
      years, the cumulative incidence of vision changes was 12.4% (CI95 6.0-18.7%), 
      peripheral neuropathy 10.3% (CI95 4.5-16.1%), and memory or cognitive change 7.6% 
      (CI95 2.5-12.7%). We did not identify any association between specific therapies 
      and the development of cardiac and neurologic AEs. APL is a highly curable 
      leukemia; further efforts are needed to address incident chronic AEs, with 
      particular focus on cardiac and neurological care.
FAU - Kim, Peter Geon
AU  - Kim PG
AD  - Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, 
      USA.
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
FAU - Bridgham, Kelly
AU  - Bridgham K
AD  - Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, 
      USA.
FAU - Chen, Evan C
AU  - Chen EC
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
FAU - Vidula, Mahesh K
AU  - Vidula MK
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
FAU - Pozdnyakova, Olga
AU  - Pozdnyakova O
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Brunner, Andrew M
AU  - Brunner AM
AD  - Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, 
      USA.
FAU - Fathi, Amir T
AU  - Fathi AT
AD  - Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20180505
PL  - England
TA  - Leuk Res Rep
JT  - Leukemia research reports
JID - 101608906
PMC - PMC5993355
OTO - NOTNLM
OT  - Cardiac
OT  - Leukemia
OT  - Neurologic
OT  - Outcome assessment
OT  - Promyelocytic
EDAT- 2018/06/13 06:00
MHDA- 2018/06/13 06:01
PMCR- 2018/05/05
CRDT- 2018/06/13 06:00
PHST- 2018/02/11 00:00 [received]
PHST- 2018/04/14 00:00 [revised]
PHST- 2018/05/01 00:00 [accepted]
PHST- 2018/06/13 06:00 [entrez]
PHST- 2018/06/13 06:00 [pubmed]
PHST- 2018/06/13 06:01 [medline]
PHST- 2018/05/05 00:00 [pmc-release]
AID - S2213-0489(18)30012-8 [pii]
AID - 10.1016/j.lrr.2018.05.001 [doi]
PST - epublish
SO  - Leuk Res Rep. 2018 May 5;9:79-83. doi: 10.1016/j.lrr.2018.05.001. eCollection 
      2018.